The top 100 biotech VCs: Who’s staying at the table and what do they want now?

As we all know only too well, the old playbook on biotech investing got thrown out the window with the end of the IPO boom at the beginning of 2022. We recently tracked VCs’ performance last year and listed the top 100 players in the field. And then I...

Click to view original post